TBPH Stock Recent News
TBPH LATEST HEADLINES
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial. Its stock was down 20.7% at US$9.14 before Friday's opening bell.